Races of Small Molecule Clinical Trials for the Treatment of COVID-19: An Up-to-date Comprehensive Review

Overview

Journal Drug Dev Res

Specialty Pharmacology

Date 2021 Nov 11

PMID 34762760

Citations 16

Authors

Suwen Hu

Songwei Jiang

Xiang Qi

Renren Bai

Xiang-Yang Ye

Tian Xie

Affiliations

Soon will be listed here.

Abstract

The coronavirus disease-19 (COVID-19) pandemic has become a global threat since its first outbreak at the end of 2019. Several review articles have been published recently, focusing on the aspects of target biology, drug repurposing, and mechanisms of action (MOAs) for potential treatment. This review gathers all small molecules currently in active clinical trials, categorizes them into six sub-classes, and summarizes their clinical progress. The aim is to provide the researchers from both pharmaceutical industries and academic institutes with the handful information and dataset to accelerate their research programs in searching effective small molecule therapy for treatment of COVID-19.

Citing Articles

Harnessing the FOXO-SIRT1 axis: insights into cellular stress, metabolism, and aging.

Gupta S, Afzal M, Agrawal N, Almalki W, Rana M, Gangola S Biogerontology. 2025; 26(2):65.

PMID: 40011269 DOI: 10.1007/s10522-025-10207-0.

Hypoxia-inducible factor and cellular senescence in pulmonary aging and disease.

Thapa R, Marianesan A, Rekha A, Ganesan S, Kumari M, Bhat A Biogerontology. 2025; 26(2):64.

PMID: 40011266 PMC: 11865175. DOI: 10.1007/s10522-025-10208-z.

Novel coumarin-based acetohydrazide-1,2,3-triazole derivatives as urease enzyme inhibitors: Synthesis, evaluation, and molecular dynamics simulation studies.

Sepehrmansourie H, Azimi M, Ebadi A, Chehardoli G, Zolfigol M, Amanlou M Heliyon. 2025; 11(1):e41321.

PMID: 39958735 PMC: 11825259. DOI: 10.1016/j.heliyon.2024.e41321.

On QSPR analysis of pulmonary cancer drugs using python-driven topological modeling.

Qin H, Hussain M, Hanif M, Siddiqui M, Hussain Z, Fiidow M Sci Rep. 2025; 15(1):3965.

PMID: 39893301 PMC: 11787360. DOI: 10.1038/s41598-025-88419-0.

Exploring the potential of some natural indoles as antiviral agents: quantum chemical analysis, inverse molecular docking, and affinity calculations.

Belal A, Abdou A, Miski S, Ali M, Ghamry H, Obaidullah A Front Chem. 2025; 12:1521298.

PMID: 39886558 PMC: 11779707. DOI: 10.3389/fchem.2024.1521298.

References

Koenig L, Boehmer D, Metzger P, Schnurr M, Endres S, Rothenfusser S . Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19. J Exp Med. 2020; 217(9). PMC: 7365736. DOI: 10.1084/jem.20201342. View

Imran M, Arora M, Asdaq S, Khan S, Alaqel S, Alshammari M . Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19. Molecules. 2021; 26(19). PMC: 8510125. DOI: 10.3390/molecules26195795. View

Ju J, Li X, Kumar S, Jockusch S, Chien M, Tao C . Nucleotide analogues as inhibitors of SARS-CoV Polymerase. Pharmacol Res Perspect. 2020; 8(6):e00674. PMC: 7596664. DOI: 10.1002/prp2.674. View

Good S, Westover J, Jung K, Zhou X, Moussa A, La Colla P . AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 and a Promising Oral Antiviral for Treatment of COVID-19. Antimicrob Agents Chemother. 2021; 65(4). PMC: 8097421. DOI: 10.1128/AAC.02479-20. View

Lu L, Zhang H, Zhan M, Jiang J, Yin H, Dauphars D . Preventing Mortality in COVID-19 Patients: Which Cytokine to Target in a Raging Storm?. Front Cell Dev Biol. 2020; 8:677. PMC: 7379422. DOI: 10.3389/fcell.2020.00677. View

Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H . Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020; 130(5):2620-2629. PMC: 7190990. DOI: 10.1172/JCI137244. View

Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

Maggio R, Corsini G . Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection. Pharmacol Res. 2020; 157:104837. PMC: 7175911. DOI: 10.1016/j.phrs.2020.104837. View

Xu J, Shi P, Li H, Zhou J . Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential. ACS Infect Dis. 2020; 6(5):909-915. PMC: 7098069. DOI: 10.1021/acsinfecdis.0c00052. View

10.

Liaudet L, Szabo C . Blocking mineralocorticoid receptor with spironolactone may have a wide range of therapeutic actions in severe COVID-19 disease. Crit Care. 2020; 24(1):318. PMC: 7278213. DOI: 10.1186/s13054-020-03055-6. View

11.

Weir E, Thenappan T, Bhargava M, Chen Y . Does vitamin D deficiency increase the severity of COVID-19?. Clin Med (Lond). 2020; 20(4):e107-e108. PMC: 7385774. DOI: 10.7861/clinmed.2020-0301. View

12.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

13.

Haritha C, Sharun K, Jose B . Ebselen, a new candidate therapeutic against SARS-CoV-2. Int J Surg. 2020; 84:53-56. PMC: 7583587. DOI: 10.1016/j.ijsu.2020.10.018. View

14.

Valencia D . Brief Review on COVID-19: The 2020 Pandemic Caused by SARS-CoV-2. Cureus. 2020; 12(3):e7386. PMC: 7179986. DOI: 10.7759/cureus.7386. View

15.

Sayad B, Sobhani M, Khodarahmi R . Sofosbuvir as Repurposed Antiviral Drug Against COVID-19: Why Were We Convinced to Evaluate the Drug in a Registered/Approved Clinical Trial?. Arch Med Res. 2020; 51(6):577-581. PMC: 7188631. DOI: 10.1016/j.arcmed.2020.04.018. View

16.

Bagca B, Biray Avci C . The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19. Cytokine Growth Factor Rev. 2020; 54:51-62. PMC: 7305753. DOI: 10.1016/j.cytogfr.2020.06.013. View

17.

Cava C, Bertoli G, Castiglioni I . In Silico Discovery of Candidate Drugs against Covid-19. Viruses. 2020; 12(4). PMC: 7232366. DOI: 10.3390/v12040404. View

18.

de Leon-Rendon J, Hurtado-Salazar C, Yamamoto-Furusho J . Aspects of inflammatory bowel disease during the COVID-19 pandemic and general considerations. Rev Gastroenterol Mex (Engl Ed). 2020; 85(3):295-302. PMC: 7245301. DOI: 10.1016/j.rgmx.2020.05.001. View

19.

Hunt C, Chakravorty N, Annan G, Habibzadeh N, Schorah C . The clinical effects of vitamin C supplementation in elderly hospitalised patients with acute respiratory infections. Int J Vitam Nutr Res. 1994; 64(3):212-9. View

20.

Sanchis-Gomar F, Lavie C, Morin D, Perez-Quilis C, Laukkanen J, Perez M . Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection?. Am J Cardiovasc Drugs. 2020; 20(5):413-418. PMC: 7394926. DOI: 10.1007/s40256-020-00429-7. View